AstraZeneca's Imfinzi Achieves Positive Results in Phase 3 Trial
28 Ottobre 2019 - 5:20PM
Dow Jones News
By Adria Calatayud
AstraZeneca PLC (AZN.LN) said Monday that its Imfinzi drug
achieved positive results in a phase 3 trial in
previously-untreated metastatic non-small cell lung cancer.
The U.K. pharmaceutical company said the trial met a primary
endpoint by showing a statistically significant and clinically
meaningful improvement in the final progression-free survival
analysis in patients treated with a combination of Imfinzi and five
standard-of-care platinum-based chemotherapy options versus
chemotherapy alone.
The triple combination of Imfinzi plus tremelimumab and
chemotherapy also demonstrated a statistically significant and
clinically meaningful PFS improvement versus chemotherapy alone as
a key secondary endpoint, AstraZeneca said.
The company said both Imfinzi and Imfinzi plus tremelimumab
delayed disease progression in a phase 3 study for first-line
treatment of metastatic non-small cell lung cancer.
The trial will continue to assess the additional primary
endpoint of overall survival with data anticipated in 2020,
AstraZeneca said.
Shares in London at 1544 GMT were up 2.1% at 7,536 pence.
Write to Adria Calatayud at
adria.calatayudvaello@dowjones.com
(END) Dow Jones Newswires
October 28, 2019 12:05 ET (16:05 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024
